<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Endometrial cancer: Pathology and classification</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Endometrial cancer: Pathology and classification</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Endometrial cancer: Pathology and classification</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jutta Huvila, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jessica N McAlpine, MD, FACOG, FRCPSC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rochelle L Garcia, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Don S Dizon, MD, FACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3742732479"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Endometrial cancers (ECs) comprise a variety of neoplasms with variable patient outcomes/prognosis. </p><p>Traditionally, EC has been classified by histomorphologic features and stratified into the more common, lower-risk, estrogen-driven cancers (type I) and the less common, more clinically aggressive/unfavorable, nonestrogen-driven cancers (type II). However, this approach does not adequately capture the complexity of these neoplasms, and histomorphologic classification has been demonstrated to be poorly reproducible in ECs, particularly for grade and histotype assignment. Thus, the World Health Organization (WHO) and International Federation of Gynecology and Obstetrics (FIGO) have subsequently developed other classification systems that incorporate molecular features to provide more objective, reproducible categorization, and that help inform prognosis and may be used to guide treatment decisions. </p><p>The pathology and classification of EC are discussed here; other related content is reviewed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16917.html" rel="external">"Overview of resectable endometrial carcinoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16924.html" rel="external">"Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3251.html" rel="external">"Endometrial carcinoma: Staging and surgical treatment"</a>.)</p><p></p><p class="headingAnchor" id="H3790059044"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>The classification of EC has evolved over time. </p><p class="headingAnchor" id="H986983136"><span class="h2">Traditional classification system</span><span class="headingEndMark"> — </span>In 1983, two clinicopathogenetic types of EC (type I and type II) were described based on endocrine and metabolic influences, pathologic features, and prognosis [<a href="#rid1">1</a>]. In this classification system, type I ECs (the majority of ECs) include those that are estrogen driven, mostly endometrioid histology, lower grade, have less myometrial invasion, and a more favorable prognosis. By contrast, type II ECs comprise a diverse mix of high-grade, clinically aggressive histologies (eg, serous, clear cell), with a poor response rate to progestogens and poor outcomes.</p><p>This classification system, although helpful in providing a conceptual framework for understanding EC, does not capture the biological diversity or diversity of clinical outcomes of some histotypes (eg, grade 3 endometrioid cancers, mixed ECs), which do not always fit neatly into one of the two categories  (<a class="graphic graphic_figure graphicRef128413" href="/d/graphic/128413.html" rel="external">figure 1</a>). </p><p class="headingAnchor" id="H3048941485"><span class="h2">WHO categorization</span><span class="headingEndMark"> — </span>The 5<sup>th</sup> edition of the World Health Organization (WHO) system, published in 2020, histologically classifies EC into the following subgroups  (<a class="graphic graphic_table graphicRef95023" href="/d/graphic/95023.html" rel="external">table 1</a>): endometrioid carcinoma, serous carcinoma, clear cell carcinoma, mixed carcinoma, undifferentiated/dedifferentiated carcinoma, carcinosarcoma, and rare EC subtypes [<a href="#rid2">2</a>]. </p><p>The WHO also recommends the integration of molecular characteristics to further categorize these tumors and to help predict prognosis. This is discussed in detail below. (See <a class="local">'Integration of molecular subtypes'</a> below.)</p><p class="headingAnchor" id="H887530243"><span class="h2">FIGO categorization</span><span class="headingEndMark"> — </span>The International Federation of Gynecology and Obstetrics (FIGO) 2023 staging system also divides EC into two categories: aggressive and less aggressive tumors [<a href="#rid3">3</a>]. Details of the 2023 FIGO staging system are presented in the tables  (<a class="graphic graphic_table graphicRef141918" href="/d/graphic/141918.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef141963" href="/d/graphic/141963.html" rel="external">table 3</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/16917.html" rel="external">"Overview of resectable endometrial carcinoma", section on 'Histopathology'</a> and  <a class="medical medical_review" href="/d/html/3251.html" rel="external">"Endometrial carcinoma: Staging and surgical treatment", section on 'Staging system'</a>.)</p><p>The FIGO 2023 guidelines also recommend the integration of molecular subtypes, when feasible. (See <a class="local">'Integration of molecular subtypes'</a> below and  <a class="medical medical_review" href="/d/html/16917.html" rel="external">"Overview of resectable endometrial carcinoma", section on 'Molecular factors'</a>.)</p><p class="headingAnchor" id="H628665257"><span class="h1">INTEGRATION OF MOLECULAR SUBTYPES</span></p><p class="headingAnchor" id="H3250295658"><span class="h2">Clinical importance</span><span class="headingEndMark"> — </span>Molecular classification has been integrated into risk stratification systems and expert clinical guidelines, including the World Health Organization (WHO), European Society of Gynaecological Oncology (ESGO), European Society for Radiotherapy and Oncology (ESTRO), European Society of Pathology (ESP), European Society of Medical Oncology (ESMO), National Comprehensive Cancer Network (NCCN), and International Federation of Gynecology and Obstetrics (FIGO) [<a href="#rid2">2-6</a>]. </p><p>Incorporating the molecular subtype offers more consistent categorization of ECs and provides both predictive and prognostic information [<a href="#rid3">3,7</a>], and a framework for research endeavors [<a href="#rid8">8-18</a>] and clinical trials [<a href="#rid19">19-25</a>]. The prognostic value of molecular classification has consistently been demonstrated, with predictive value emerging with respect to response to radiotherapy [<a href="#rid26">26,27</a>], chemotherapy [<a href="#rid20">20,24,25,28</a>], and targeted treatment [<a href="#rid20">20,22,29-33</a>]. It is imperative that clinicians are familiar with the key molecular features that enable EC classification, are able to interpret molecular results provided in pathology reports (see <a class="local">'Pathology reporting'</a> below), and are aware of the implications these features have on clinical care [<a href="#rid34">34</a>]. </p><p>Molecular subtype assignment can be determined from diagnostic endometrial biopsies or curettings, showing high concordance with classification performed on the hysterectomy specimen [<a href="#rid15">15,35-37</a>]. Approximately 3 percent of ECs have more than one molecular feature [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H3322133652"><span class="h2">Subtypes</span><span class="headingEndMark"> — </span>In 2013, The Cancer Genome Atlas (TCGA) used genomic, transcriptomic, and proteomic analyses to characterize over 370 ECs, identifying four molecular subtypes based on tumor cell genomic architecture with distinct prognostic outcomes [<a href="#rid7">7</a>] and clinicopathologic features  (<a class="graphic graphic_table graphicRef128149" href="/d/graphic/128149.html" rel="external">table 4</a>). Subsequently, a clinically applicable molecular classification system that can be performed on standard formalin-fixed, paraffin-embedded material and serve as a surrogate for diagnosis of the four TCGA molecular subtypes was developed [<a href="#rid7">7,38-41</a>]. This algorithm arose independently from two research teams, and subsequently through international collaboration has clarified several critical features: consensus on the nomenclature and color designations for the four molecular subtypes [<a href="#rid2">2</a>], and characterization of "multiple classifier" ECs that harbor more than one key classification feature (eg, a tumor with both a <em>POLE</em> mutation and p53 abnormality and/or mismatch repair deficiency). The order of segregation shown in the figure  (<a class="graphic graphic_figure graphicRef128147" href="/d/graphic/128147.html" rel="external">figure 2</a>) reflects the now agreed upon categorization of these rare tumors.</p><p>The four molecular subtypes of EC are as follows, with WHO nomenclature given [<a href="#rid42">42</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>DNA polymerase epsilon (</strong><strong><em>POLE</em></strong><strong>)-mutated subtype (</strong><strong><em>POLE</em></strong><strong>mut; TCGA "</strong><strong><em>POLE</em></strong><strong> [ultramutated]," previously "</strong><strong><em>POLE</em></strong><strong>," or "</strong><strong><em>POLE</em></strong><strong> EDM") </strong>– These are copy number (CN) stable ECs with recurrent mutations in the exonuclease domain of <em>POLE</em>, a gene involved in DNA replication and repair [<a href="#rid43">43-46</a>]. In-depth characterization of ECs with <em>POLE</em> mutations, both within and outside the exonuclease domain, has generated a structured scoring system that limits the assignment of <em>POLE</em>mut to a list of 11 established pathogenic mutations [<a href="#rid18">18</a>]. These tumors have one of the highest somatic mutation frequencies of any solid tumors, frequently exceeding 100 mutations per megabase (Mb). Often, but not exclusively, of endometrioid histologic type, <em>POLE</em>mut ECs have prominent tumor-infiltrating lymphocytes (TILs).</p><p></p><p class="bulletIndent1">Patients with<em> POLE</em>mut ECs tend to be younger and thinner, and despite often having seemingly aggressive pathologic features (eg, high-grade, lymphovascular space invasion), they have highly favorable outcomes (&gt;96 percent five-year survival) confirmed across multiple studies [<a href="#rid47">47-51</a>].</p><p></p><p class="bulletIndent1">In an individual patient data meta-analysis of all reported <em>POLE</em>mut ECs, adjuvant therapy was not associated with improved outcomes for women with pathogenic <em>POLE</em> mutations, supporting de-escalation of therapy in clinical trials [<a href="#rid51">51</a>]. Two prospective studies are assessing the possibility of de-escalation of therapy in EC: (1) PORTEC-4a is a multicenter randomized phase III trial in patients with high-intermediate risk EC that has completed accrual but has not yet reported results [<a href="#rid52">52-54</a>], and (2) Tailored Adjuvant Therapy in <em>POLE</em>-mutated and p53-wildtype/no specific molecular profile (NSMP) Early Stage Endometrial Cancer (RAINBO Blue and TAPER) is a prospective cohort study in early-stage EC [<a href="#rid51">51,54</a>].</p><p></p><p class="bulletIndent1">Immunotherapy may be an option in the rare scenario of recurrent <em>POLE</em>mut EC given the high observed TIL [<a href="#rid55">55-57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mismatch repair-deficient subtype (MMRd; TCGA "MSI [hypermutated]," previously "MMR-D")</strong> – These EC have low levels of somatic CN alterations but a very high mutational burden and high TIL secondary to dysfunctional mismatch repair (MMR) proteins (mutL homolog 1 [MLH1], postmeiotic segregation 2 [PMS2], mutS homolog 2 [MSH2], or mutS homolog 6 [MSH6]) [<a href="#rid58">58</a>]. Epigenetic silencing of MLH1 is responsible for the majority of this subtype, but it also includes both somatic and germline mutations (Lynch syndrome (see  <a class="medical medical_review" href="/d/html/3224.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and prevention of endometrial and ovarian cancer"</a>)) in any of the MMR genes. This molecular subtype is associated with a high tumor mutational frequency (&gt;10 mutations/Mb).</p><p></p><p class="bulletIndent1">The receptor tyrosine kinase (RTK)/RAS/beta-catenin pathways and phosphatase and tensin homolog (<em>PTEN</em>)/phosphoinositide 3-kinase (PI3K) signaling pathways are commonly involved in "microsatellite instability" (MSI) ECs (69.5 and &gt;90 percent of cases, respectively) [<a href="#rid7">7,59</a>]. Studies on MSI status and clinical outcomes in EC have had discordant results. Retrospective data suggest increased disease-specific survival in stage IB/II high-grade MMRd endometrioid EC treated with radiation [<a href="#rid26">26</a>], but similar recurrence-free survival was found in a combined cohort of early stage intermediate and high-intermediate risk MMRd EC [<a href="#rid27">27</a>]. The US Food and Drug Administration (FDA) has approved the use of immune checkpoint inhibitors for metastatic or recurrent MSI ECs with marked response rates observed even in the setting of heavily pretreated disease [<a href="#rid60">60,61</a>]. Two landmark clinical trials demonstrated improvement in outcomes in patients with primary advanced or first recurrence ECs treated with immune checkpoint inhibitors in combination with standard chemotherapy [<a href="#rid62">62,63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No specific molecular profile (NSMP; TCGA copy-number low [endometrioid], previously also termed p53 wild-type ["p53wt"] and "NSMP/p53wt")</strong> – This third molecular subtype is genomically stable, MMR proficient, with moderate mutational load ECs (frequently involving PI3K/Akt and Wnt/catenin beta 1 [<em>CTNNB1</em>] signaling pathways), and has intermediate to favorable outcomes. NSMP ECs have normal p53 immunohistochemical expression and are <em>POLE </em>wildtype. This group encompasses mostly endometrioid neoplasms with estrogen and progesterone receptor (ER, PR) positivity and high response rates to hormonal therapy. Endometrioid ECs of NSMP subtype that are ER negative have been shown to have an unfavorable prognosis [<a href="#rid64">64,65</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>p53 abnormal (p53abn; TCGA copy number [CN] high [serous-like])</strong> – The fourth molecular subtype has high somatic CN alterations and mutational profiles similar to high-grade serous ovarian and basal-like breast carcinomas<em>.</em> <em>TP53</em> mutations are characteristic for this group. The p53abn cases are associated with a poor prognosis and responsible for 50 to 70 percent of EC mortality. The approximate proportions of p53abn ECs for each histologic type are as follows: serous carcinoma (93 percent), carcinosarcoma (85 percent), clear cell carcinoma (38 percent), grade 3 endometrioid carcinoma (22 percent), and grade 1 or 2 endometrioid carcinoma (5 percent) [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1">Data from patients enrolled in the PORTEC-3 trial and in international cohorts outside of clinical trials suggest that patients with p53abn ECs treated with chemotherapy in addition to radiation have superior outcomes as compared with those who received radiation [<a href="#rid25">25,67</a>]. </p><p></p><p class="bulletIndent1">Human epidermal growth factor receptor 2<em> </em>(<em>HER2</em>) amplification has been reported in approximately 20 to 25 percent of CN high/p53abn ECs and successfully targeted in serous carcinomas [<a href="#rid30">30,68,69</a>]. Over 40 percent of CN high/p53abn ECs have homologous recombination deficiency (HRD) based on<em> RAD51</em> foci formation, with a lower percentage showing HRD based on mutational signatures [<a href="#rid29">29,70</a>] presenting another potential target for this molecular subtype. Breast cancer susceptibility genes (<em>BRCA1/</em>2) mutation carriers appear to be at increased risk for p53abn EC, with the highest risk within <em>BRCA1</em> mutation carriers [<a href="#rid71">71</a>]. Finally, antiangiogenic agents, alone or in combination appear to add value in the treatment of advanced or recurrent p53abn EC [<a href="#rid31">31,72,73</a>].</p><p></p><p class="headingAnchor" id="H3075383113"><span class="h1">RISK STRATIFICATION</span><span class="headingEndMark"> — </span>Multiple risk stratification systems for EC have been developed [<a href="#rid19">19,74-78</a>]. Distinguishing between patients who may be cured by surgery alone and those at significant risk of both local and distant recurrence, and therefore in need of adjuvant therapy, remains a tremendous challenge for clinicians caring for patients with EC. </p><p>Risk stratification and approach to adjuvant therapy are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/16917.html" rel="external">"Overview of resectable endometrial carcinoma", section on 'Role of adjuvant therapy'</a>.)</p><p class="headingAnchor" id="H1260416927"><span class="h1">HISTOGENESIS AND PRECURSOR LESIONS</span><span class="headingEndMark"> — </span>ECs that arise from atypical endometrial hyperplasia/endometrioid intraepithelial neoplasia (AEH/EIN) can be associated with any of the four molecular subtypes described above; <em>POLE</em> mutations and loss of mismatch repair (MMR) expression are typically seen in AEH/EIN associated with <em>POLE</em>mut and MMR-deficient (MMRd) EC, respectively, indicating that these alterations are early events in oncogenesis. Serous EC and carcinosarcoma mostly arise from serous endometrial intraepithelial carcinoma (SEIC), but some arise from AEH/EIN (and are associated with mutations in phosphatase and tensin homolog [<em>PTEN</em>]).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atypical endometrial hyperplasia/endometrioid intraepithelial neoplasia</strong> is characterized by a clonal proliferation of complex endometrial glands such that glands predominate over stroma. The glandular epithelial cells have mild or moderate cytologic atypia, with nuclear stratification and enlargement, sometimes with prominent nucleoli.</p><p></p><p class="bulletIndent1">AEH/EIN is associated with unopposed estrogenic stimulation and acquisition of mutations in<em> PTEN, </em>Kirsten rat sarcoma viral oncogene homolog (<em>KRAS</em>)<em>, </em>phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (<em>PI3KCA</em>)<em>, </em>PI3K/Akt and Wnt/catenin beta 1 (<em>CTNNB1</em>), and/or AT-rich interaction domain 1A (<em>ARID1A</em>). It gives rise to MMRd and <em>POLE</em>mut ECs, some of the p53-mutated ECs, as well as no specific molecular profile (NSMP) ECs. In an individual patient, the mutational/molecular profiles of AEH/EIN and the concurrent EC are highly concordant [<a href="#rid35">35,79,80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serous endometrial intraepithelial carcinoma </strong>– In SEIC, the preexisting endometrial glands are lined by markedly atypical glandular epithelial cells. These epithelial cells show nucleomegaly; typically are less polarized; have rounded, more atypical and pleomorphic nuclei and high nucleus-to-cytoplasm (n:c) ratios; and are associated with a high proliferative index.</p><p></p><p class="bulletIndent1">Tumor protein 53 (<em>TP53</em>) mutations<strong> </strong>are the defining feature of SEIC, and mutations in<strong> </strong>protein phosphatase 2, structural/regulatory subunit alpha (<em>PPP2R1A</em>) are common. SEIC is the precursor of many p53abn ECs, but the percentage is not known.</p><p></p><p class="headingAnchor" id="H1420061797"><span class="h1">HISTOLOGIC TYPES</span><span class="headingEndMark"> — </span>The World Health Organization (WHO) histologically classifies EC into the following subgroups  (<a class="graphic graphic_table graphicRef95023" href="/d/graphic/95023.html" rel="external">table 1</a>). (See <a class="local">'WHO categorization'</a> above.)</p><p class="headingAnchor" id="H585495186"><span class="h2">Endometrioid carcinoma</span><span class="headingEndMark"> — </span>Endometrioid EC is the most common EC histology, accounting for 75 to 80 percent of cases. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> – Endometrioid EC is composed of tall columnar cells lining back-to-back glands without intervening stroma (suggesting invasion). The glands have a smooth, luminal contour. Cribriform (gland within a gland) patterns are also common. Occasionally, endometrioid ECs have a prominent papillary or villoglandular growth pattern. </p><p></p><p class="bulletIndent1">Several variant types of endometrioid EC are recognized, including carcinomas with squamous differentiation, mucinous differentiation (characterized by prominent intracellular mucin within the neoplastic cells), and prominent cytoplasmic vacuoles (secretory carcinoma).</p><p></p><p class="bulletIndent1">Myometrial invasion, if present, may have either an infiltrative pattern with reactive stromal fibrosis and inflammatory cells ("desmoplastic reaction") or a more subtle pushing pattern (large nests of neoplastic cells extend into the myometrium without eliciting a stromal reaction). An unusual pattern seen with grade 1 endometrioid ECs, the microcystic elongated and fragmented pattern ("MELF"), is associated with lymphovascular space invasion and nodal metastases [<a href="#rid81">81,82</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Grade</strong> – Endometrioid ECs are graded using the International Federation of Gynecology and Obstetrics (FIGO) classification system (see <a class="local">'FIGO categorization'</a> above), which assesses the architectural pattern and nuclear grade [<a href="#rid3">3</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Grade 1</strong> – Less than 5 percent solid growth patterns  (<a class="graphic graphic_picture graphicRef108723" href="/d/graphic/108723.html" rel="external">picture 1</a>)</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Grade 2</strong> – 6 to 50 percent solid growth patterns</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Grade 3</strong> – Greater than 50 percent solid growth  (<a class="graphic graphic_picture graphicRef108724" href="/d/graphic/108724.html" rel="external">picture 2</a>)</p><p></p><p class="bulletIndent1">Squamous differentiation is common and not included in assessment of solid growth when determining grade. Marked nuclear atypia (nuclear grade 3) raises the grade by one (from 1 to 2 or from 2 to 3) [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular subtypes</strong> – Endometrioid carcinomas can be any of the four molecular subtypes (see <a class="local">'Integration of molecular subtypes'</a> above), which indicates the genetic heterogeneity within this histologic type. Many grade 3 endometrioid ECs have a genomic profile similar to serous ECs, with high copy number (CN) alterations and tumor protein 53 (<em>TP53</em>) mutations [<a href="#rid83">83-85</a>], and represent a particularly diverse subset of EC [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Most endometrioid ECs are low grade (grade 1 or 2), diagnosed at an early stage, and have a good prognosis [<a href="#rid86">86</a>]. Approximately 5 percent of low-grade endometrioid carcinomas are p53abn with worse outcomes [<a href="#rid83">83,87</a>]. Grade 3 p53abn endometrioid ECs behave more aggressively and have a poorer prognosis than other molecular subtypes of grade 3 endometrioid EC [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/3223.html" rel="external">"Treatment of low-risk endometrial cancer", section on 'Prognosis'</a>.)</p><p></p><p class="headingAnchor" id="H490063233"><span class="h2">Serous endometrial carcinoma</span><span class="headingEndMark"> — </span>Serous endometrial carcinoma (SEC) is the second most common type of EC but only accounts for approximately 10 percent of cases. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> – In SEC, the neoplastic cells form papillary structures and glands with serrated outlines. The cells have marked nuclear atypia with prominent nucleoli and numerous mitotic figures  (<a class="graphic graphic_picture graphicRef108725" href="/d/graphic/108725.html" rel="external">picture 3</a>). Occasionally, SEC is composed primarily of glands, but the marked nuclear atypia is a key to proper tumor classification. Psammoma bodies may be present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular subtypes</strong> – A very large majority of SECs are of the p53abn molecular subtype (see <a class="local">'Integration of molecular subtypes'</a> above). Human epidermal growth factor receptor 2 (<em>HER2</em>) is overexpressed/amplified/mutated in a minority of SECs and can be targeted therapeutically [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Clinically occult extrauterine disease is often present at diagnosis [<a href="#rid88">88</a>]. SEC often diffusely infiltrates the myometrium and may have extensive lymphovascular space invasion and peritoneal spread, similar to ovarian carcinoma. However, SEC confined to the endometrium (or a polyp) with minimal myometrial invasion and no distant disease after surgical staging has a good prognosis.</p><p></p><p>SEC is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/3180.html" rel="external">"Endometrial carcinoma: Serous and clear cell histologies"</a>.)</p><p class="headingAnchor" id="H3561653684"><span class="h2">Clear cell carcinoma</span><span class="headingEndMark"> — </span>Clear cell EC is an uncommon subtype, comprising &lt;5 percent of EC, and patients are usually older and postmenopausal [<a href="#rid89">89,90</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> – Clear cell ECs share morphologic features with ovarian clear cell carcinoma and have several different architectural patterns: papillary, glandular, tubulocystic, and diffuse. The neoplasm is often composed of cells with abundant clear cytoplasm  (<a class="graphic graphic_picture graphicRef108726" href="/d/graphic/108726.html" rel="external">picture 4</a>); however, eosinophilic cytoplasm, hobnail, and flat cells can also be seen. Cytologic atypia is variable, and occasional enlarged irregular nucleoli are seen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular subtypes</strong> – Clear cell ECs can be of any of the four molecular subtypes (see <a class="local">'Integration of molecular subtypes'</a> above); <em>POLE</em>mut clear cell carcinomas have the most favorable prognosis while p53abn clear cell carcinomas are associated with aggressive behavior [<a href="#rid11">11,14,91</a>]. The mismatch repair-deficient (MMRd) cases often show mixed morphology, with clear cell and endometrioid components [<a href="#rid92">92</a>].</p><p></p><p class="bulletIndent1">Clear cell ECs are typically negative for estrogen receptor (ER) protein and positive for Napsin A, which can aid in distinguishing this form of high-grade carcinoma from its mimics: SEC and the secretory variant of endometrioid EC.</p><p></p><p class="bulletIndent1">The 2020 European Society of Gynaecological Oncology (ESGO), European Society for Radiotherapy and Oncology (ESTRO), and European Society of Pathology (ESP) guidelines do not offer specific recommendations for cases of clear cell EC that have undergone molecular classification, citing insufficient evidence to direct risk group assignment and treatment in these rare cancers [<a href="#rid4">4</a>].</p><p></p><p>Clear cell endometrial carcinoma is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/3180.html" rel="external">"Endometrial carcinoma: Serous and clear cell histologies"</a>.)</p><p class="headingAnchor" id="H89215401"><span class="h2">Mixed carcinoma</span><span class="headingEndMark"> — </span>Mixed carcinomas have at least two distinct histologic components, typically endometrioid and a high-grade nonendometrioid pattern (usually serous, sometimes clear cell). These neoplasms are almost all clonal rather than being a collision between two synchronous but independent primary neoplasms and are usually the same molecular subtypes throughout (ie, they are an example of morphologic variability within a molecular subtype).</p><p class="headingAnchor" id="H3019800136"><span class="h2">Undifferentiated/dedifferentiated carcinoma</span><span class="headingEndMark"> — </span>Undifferentiated/dedifferentiated ECs<strong> </strong>are the least well understood of the major histologic types of EC [<a href="#rid93">93-95</a>].</p><p>These neoplasms have no glandular or squamous differentiation. Most express epithelial antigens (eg, cytokeratin), but this is typically focal. Dedifferentiated carcinomas are composed of International Federation of Gynecology and Obstetrics (FIGO) grade 1 or 2 endometrioid EC adjacent to areas of undifferentiated carcinoma. Undifferentiated/dedifferentiated carcinomas are frequently MMRd, often have mutations in genes encoding proteins of the switch/sucrose nonfermentable (SWI/SNF) complex, and, in most cases, do not have mutations in <em>TP53</em>. </p><p class="headingAnchor" id="H3078701589"><span class="h2">Carcinosarcoma</span><span class="headingEndMark"> — </span>Carcinosarcoma (previously known as malignant mixed Müllerian tumor) is an uncommon, aggressive, biphasic carcinoma (not sarcoma) that accounts for &lt;5 percent of ECs. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> – Carcinosarcoma is composed of a high-grade sarcoma component juxtaposed with a high-grade carcinoma. The sarcomatous component is composed of cell types intrinsic to the uterus (homologous tumors), such as endometrial stromal sarcoma or leiomyosarcoma, or cell types extrinsic to the uterus (heterologous tumors), such as chondrosarcoma or rhabdomyosarcoma. The carcinomatous component is usually high grade, frequently difficult to assign to a specific histologic type, and can show features of high-grade endometrioid carcinoma, serous carcinoma, clear cell carcinoma, or undifferentiated carcinoma  (<a class="graphic graphic_picture graphicRef108727" href="/d/graphic/108727.html" rel="external">picture 5</a>). </p><p></p><p class="bulletIndent1">Metastatic neoplasms are purely carcinomatous or mixed carcinoma and sarcoma in over 90 percent of cases with only a few comprising pure sarcoma [<a href="#rid96">96</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular subtypes</strong> – A majority of carcinosarcomas are of the p53abn molecular subtype (90 percent of carcinosarcomas characterized by The Cancer Genome Atlas [TCGA] had <em>TP53</em> mutations), but they can also be of the other three molecular subtypes of EC [<a href="#rid97">97,98</a>]. (See <a class="local">'Integration of molecular subtypes'</a> above.)</p><p></p><p>Carcinosarcoma is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/3203.html" rel="external">"Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma"</a>.)</p><p class="headingAnchor" id="H3399148505"><span class="h2">Rare EC subtypes</span><span class="headingEndMark"> — </span>Mesonephric and mesonephric-like adenocarcinoma of the uterine corpus resemble morphologically their better described counterparts in the uterine cervix. They have a characteristic immunophenotype (GATA-binding protein 3 [GATA3] positive, thyroid transcription factor-1 [TTF1] positive, ER negative) and are associated with aggressive behavior.</p><p>Squamous cell carcinomas of the endometrium, in their pure form, are rare and must be distinguished from the much more common endometrioid adenocarcinomas with squamous differentiation, which can be predominantly squamous. They can arise in association with chronic inflammation and squamous metaplasia.</p><p class="headingAnchor" id="H492773594"><span class="h1">PATHOLOGY REPORTING</span><span class="headingEndMark"> — </span>The International Collaboration on Cancer Reporting (ICCR) determines the core and noncore factors that should be reported for EC resection specimens and their EC histopathology reporting guide can be found <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.iccr-cancer.org%2Fdatasets%2Fpublished-datasets%2Ffemale-reproductive%2Fendometrial%2F&amp;token=0n6JQEaJNCtIXF85SaheCiG0a%2BIynZ8imh3Gm%2BMPsC6QzmSTDbXW%2ByZ7lt4a%2B4Qrz1chBy56IpAh%2B6c4mx6pip3PXmQZR5OZGb2ZpIkhYF8%3D&amp;TOPIC_ID=3192" target="_blank">online</a> [<a href="#rid99">99</a>].</p><p>The diagnostic report for EC based on an endometrial biopsy or curetting specimen includes neoplasm histology and, for endometrioid carcinomas, grade. The following is a pragmatic approach to use of molecular markers at this time, acknowledging that this is an area in evolution.</p><p class="bulletIndent1"><span class="glyph">●</span>Perform mismatch repair (MMR) immunohistochemistry (or microsatellite instability [MSI] assay) in all EC cases. In most institutions, the most cost-effective approach is to screen with mutL homolog 6 (MSH6) and postmeiotic segregation 2 (PMS2) immunohistochemistry alone, with subsequent mutL homolog 2 (MSH2) or mutL homolog 1 (MLH1) immunohistochemistry when needed. The determination of MMR expression is recommended by the Society of Gynecologic Oncology (SGO) as part of Lynch syndrome screening in EC patients. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Protein 53 (p53) immunostaining (or molecular testing) should be performed in all high-grade endometrioid and clear cell ECs and in low-grade neoplasms with any unusual features, such as increased nuclear atypia or mitotic activity. The role of p53 immunostaining in "typical" low-grade endometrioid carcinomas is uncertain; most centers do not routinely perform p53 testing of grade 1 or grade 2 EC as relatively few will show abnormal p53 immunostaining. Because patients with p53abn EC, irrespective of histology, will be candidates for adjuvant chemotherapy based on data from PORTEC-3 [<a href="#rid25">25</a>], there is a trend towards increased p53 testing in EC, with reflex p53 immunostaining of all EC performed in some centers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>POLE</em> mutational testing may be performed for qualification in clinical trials and in clinical practice where adjuvant treatment decisions would be altered. The British Association of Gyneacological Pathologist (BAGP) recommends <em>POLE</em> testing in all stage I/II cases with mismatch repair-deficient (MMRd) and/or p53 abnormalities, nonendometrioid histology, poorly differentiated (grade 3) endometrioid histotype and low-grade endometrioid histology together with high-risk factors such as lymphovascular space invasion, deep myometrial invasion, and estrogen receptor (ER) negativity [<a href="#rid100">100</a>]. Subclonal abnormal p53abn immunostaining could also be an indication as approximately one-half of ECs with subclonal complete loss or overexpression of p53 are <em>POLE</em>mut and thus associated with a favorable (<em>POLE</em>mut) rather than unfavourable (p53abn) EC molecular subtype. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ER immunohistochemical staining is an important stratification feature within no specific molecular profile (NSMP) ECs and can also be performed on diagnostic biopsy/curettings [<a href="#rid64">64,65</a>] to inform prognosis, guide treatment decisions, and determine which individuals need <em>POLE</em> testing [<a href="#rid100">100</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human epidermal growth factor receptor 2 (HER2) overexpression or amplification can be assessed by immunohistochemistry or in situ hybridization, respectively, and can provide both prognostic and predictive value within serous/p53abn ECs [<a href="#rid30">30,69,101</a>].</p><p></p><p class="headingAnchor" id="H2554720105"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/121144.html" rel="external">"Society guideline links: Uterine cancer"</a>.)</p><p class="headingAnchor" id="H1869881032"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> <strong>systems </strong>–<strong> </strong>The classification of endometrial cancers (ECs) has evolved over time. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Traditional</strong> – ECs have traditionally been classified as type I or type II. Type I ECs are estrogen driven, mostly endometrioid histology, lower grade, typically have less myometrial invasion than type II EC, and are associated with a favorable prognosis. By contrast, type II ECs comprise a diverse mix of high-grade, clinically aggressive histologies (eg, serous, clear cell), with a poor response rate to progestogens and a poor outcome. (See <a class="local">'Traditional classification system'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>WHO</strong> – The World Health Organization (WHO) histologically classifies EC into the following subgroups  (<a class="graphic graphic_table graphicRef95023" href="/d/graphic/95023.html" rel="external">table 1</a>): endometrioid, serous, clear cell, mixed, and undifferentiated/dedifferentiated carcinoma, carcinosarcoma, and rare EC subtypes. (See <a class="local">'WHO categorization'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>FIGO</strong> – The International Federation of Gynecology and Obstetrics (FIGO) 2023 staging system divides histological types into aggressive and less aggressive tumors  (<a class="graphic graphic_table graphicRef141918" href="/d/graphic/141918.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef141963" href="/d/graphic/141963.html" rel="external">table 3</a>); this is described in detail separately. (See <a class="local">'FIGO categorization'</a> above and  <a class="medical medical_review" href="/d/html/16917.html" rel="external">"Overview of resectable endometrial carcinoma", section on 'Histopathology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Integration of molecular subtypes</strong> – Molecular features and subtyping are integrated into pathology reporting, where available, offering more consistent categorization of ECs and providing both predictive and prognostic information. The four molecular subtypes of EC are <em>POLE</em> mutant (<em>POLE</em>mut), mismatch repair-deficient (MMRd), no specific molecular profile<strong> </strong>(NSMP), and p53 abnormal<strong> </strong>(p53abn)  (<a class="graphic graphic_table graphicRef128149" href="/d/graphic/128149.html" rel="external">table 4</a>). (See <a class="local">'Integration of molecular subtypes'</a> above and <a class="local">'Pathology reporting'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precursor lesions</strong> – ECs that arise from endometrial hyperplasia with atypia/endometrioid intraepithelial neoplasm (AEH/EIN) can be associated with any of the four molecular subtypes of EC; <em>POLE</em> mutations and mismatch repair (MMR) loss of expression are typically seen in AEH/EIN associated with <em>POLE</em>mut and MMRd EC, respectively, indicating that they are early events in oncogenesis. Serous EC and carcinosarcoma mostly arise from serous endometrial intraepithelial carcinoma, but some arise from AEH/EIN (and are associated with mutations in phosphatase and tensin homolog [<em>PTEN</em>]). (See <a class="local">'Histogenesis and precursor lesions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology reporting</strong> – The International Collaboration on Cancer Reporting (ICCR) determines the core and noncore factors that should be reported for EC resection specimens, and their EC histopathology reporting guide can be found <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.iccr-cancer.org%2Fdatasets%2Fpublished-datasets%2Ffemale-reproductive%2Fendometrial%2F&amp;token=0n6JQEaJNCtIXF85SaheCiG0a%2BIynZ8imh3Gm%2BMPsC6QzmSTDbXW%2ByZ7lt4a%2B4Qrz1chBy56IpAh%2B6c4mx6pip3PXmQZR5OZGb2ZpIkhYF8%3D&amp;TOPIC_ID=3192" target="_blank">online</a>. (See <a class="local">'Pathology reporting'</a> above.)</p><p></p><p class="headingAnchor" id="H2286219346"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Lesley Lomo, MD; Jonathan Hecht, MD, PhD; and Margaret Steinhoff, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15:10.</a></li><li class="breakAll">WHO Classification of Tumours Editorial Board. Female Genital Tumours, 5th ed, IARC, 2020. Vol 4.</li><li><a class="nounderline abstract_t">Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023; 162:383.</a></li><li><a class="nounderline abstract_t">Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021; 31:12.</a></li><li class="breakAll">NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Uterine neoplasms, 2021. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1473 (Accessed on June 12, 2021).</li><li><a class="nounderline abstract_t">Oaknin A, Bosse TJ, Creutzberg CL, et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33:860.</a></li><li><a class="nounderline abstract_t">Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497:67.</a></li><li><a class="nounderline abstract_t">Raffone A, Travaglino A, Mascolo M, et al. TCGA molecular groups of endometrial cancer: Pooled data about prognosis. Gynecol Oncol 2019; 155:374.</a></li><li><a class="nounderline abstract_t">Travaglino A, Raffone A, Stradella C, et al. Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups. Arch Gynecol Obstet 2020; 301:1355.</a></li><li><a class="nounderline abstract_t">Travaglino A, Raffone A, Mollo A, et al. TCGA molecular subgroups and FIGO grade in endometrial endometrioid carcinoma. Arch Gynecol Obstet 2020; 301:1117.</a></li><li><a class="nounderline abstract_t">Travaglino A, Raffone A, Mascolo M, et al. Clear cell endometrial carcinoma and the TCGA classification. Histopathology 2020; 76:336.</a></li><li><a class="nounderline abstract_t">McAlpine JN, Temkin SM, Mackay HJ. Endometrial cancer: Not your grandmother's cancer. Cancer 2016; 122:2787.</a></li><li><a class="nounderline abstract_t">Britton H, Huang L, Lum A, et al. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Gynecol Oncol 2019; 153:487.</a></li><li><a class="nounderline abstract_t">Kim SR, Cloutier BT, Leung S, et al. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification. Gynecol Oncol 2020; 158:3.</a></li><li><a class="nounderline abstract_t">Stelloo E, Nout RA, Naves LC, et al. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. Gynecol Oncol 2014; 133:197.</a></li><li><a class="nounderline abstract_t">Bosse T, Nout RA, McAlpine JN, et al. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. Am J Surg Pathol 2018; 42:561.</a></li><li><a class="nounderline abstract_t">León-Castillo A, Gilvazquez E, Nout R, et al. Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas. J Pathol 2020; 250:312.</a></li><li><a class="nounderline abstract_t">León-Castillo A, Britton H, McConechy MK, et al. Interpretation of somatic POLE mutations in endometrial carcinoma. J Pathol 2020; 250:323.</a></li><li><a class="nounderline abstract_t">Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92:744.</a></li><li><a class="nounderline abstract_t">Creutzberg CL, Leon-Castillo A, De Boer SM, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy. Ann Oncol 2019; 3-:mdz394.</a></li><li><a class="nounderline abstract_t">Randall ME, Filiaci V, McMeekin DS, et al. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. J Clin Oncol 2019; 37:1810.</a></li><li><a class="nounderline abstract_t">Hawkes AL, Quinn M, Gebski V, et al. Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial. Contemp Clin Trials 2014; 39:14.</a></li><li><a class="nounderline abstract_t">Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003; 95:160.</a></li><li><a class="nounderline abstract_t">de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 2019; 20:1273.</a></li><li><a class="nounderline abstract_t">León-Castillo A, de Boer SM, Powell ME, et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol 2020; 38:3388.</a></li><li><a class="nounderline abstract_t">Reijnen C, Küsters-Vandevelde HVN, Prinsen CF, et al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. Gynecol Oncol 2019; 154:124.</a></li><li><a class="nounderline abstract_t">Horeweg N, Nout RA, Jürgenliemk-Schulz IM, et al. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer. J Clin Oncol 2023; 41:4369.</a></li><li><a class="nounderline abstract_t">de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2018; 19:295.</a></li><li><a class="nounderline abstract_t">de Jonge MM, Auguste A, van Wijk LM, et al. Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas. Clin Cancer Res 2019; 25:1087.</a></li><li><a class="nounderline abstract_t">Fader AN, Roque DM, Siegel E, et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. J Clin Oncol 2018; 36:2044.</a></li><li><a class="nounderline abstract_t">Leslie KK, Filiaci VL, Mallen AR, et al. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol 2021; 161:113.</a></li><li><a class="nounderline abstract_t">Lorusso D, Ferrandina G, Colombo N, et al. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial. Gynecol Oncol 2019; 155:406.</a></li><li><a class="nounderline abstract_t">Jamieson A, Bosse T, McAlpine JN. The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer. Ther Adv Med Oncol 2021.</a></li><li><a class="nounderline abstract_t">Cosgrove CM, Barrington D, Backes FJ. Impact of Molecular Classification on Treatment Paradigms in Uterine Cancers. Curr Oncol Rep 2021; 23:75.</a></li><li><a class="nounderline abstract_t">Abdulfatah E, Wakeling E, Sakr S, et al. Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management. Gynecol Oncol 2019; 154:467.</a></li><li><a class="nounderline abstract_t">Kommoss S, McConechy MK, Kommoss F, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol 2018; 29:1180.</a></li><li><a class="nounderline abstract_t">Talhouk A, Hoang LN, McConechy MK, et al. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. Gynecol Oncol 2016; 143:46.</a></li><li><a class="nounderline abstract_t">Stelloo E, Nout RA, Osse EM, et al. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Clin Cancer Res 2016; 22:4215.</a></li><li><a class="nounderline abstract_t">Hoang LN, Kinloch MA, Leo JM, et al. Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup. Am J Surg Pathol 2017; 41:245.</a></li><li><a class="nounderline abstract_t">Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015; 113:299.</a></li><li><a class="nounderline abstract_t">Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer 2017; 123:802.</a></li><li><a class="nounderline abstract_t">Crosbie EJ, Kitson SJ, McAlpine JN, et al. Endometrial cancer. Lancet 2022; 399:1412.</a></li><li><a class="nounderline abstract_t">Shevelev IV, Hübscher U. The 3' 5' exonucleases. Nat Rev Mol Cell Biol 2002; 3:364.</a></li><li><a class="nounderline abstract_t">Rayner E, van Gool IC, Palles C, et al. A panoply of errors: polymerase proofreading domain mutations in cancer. Nat Rev Cancer 2016; 16:71.</a></li><li><a class="nounderline abstract_t">Henninger EE, Pursell ZF. DNA polymerase ε and its roles in genome stability. IUBMB Life 2014; 66:339.</a></li><li><a class="nounderline abstract_t">Church DN, Briggs SE, Palles C, et al. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer. Hum Mol Genet 2013; 22:2820.</a></li><li><a class="nounderline abstract_t">Church DN, Stelloo E, Nout RA, et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst 2015; 107:402.</a></li><li><a class="nounderline abstract_t">McConechy MK, Talhouk A, Leung S, et al. Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis. Clin Cancer Res 2016; 22:2865.</a></li><li><a class="nounderline abstract_t">Meng B, Hoang LN, McIntyre JB, et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol Oncol 2014; 134:15.</a></li><li><a class="nounderline abstract_t">Stasenko M, Tunnage I, Ashley CW, et al. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Gynecol Oncol 2020; 156:194.</a></li><li><a class="nounderline abstract_t">McAlpine JN, Chiu DS, Nout RA, et al. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis. Cancer 2021; 127:2409.</a></li><li class="breakAll">PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer (PORTEC-4a). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03469674 (Accessed on May 14, 2020).</li><li><a class="nounderline abstract_t">van den Heerik ASVM, Horeweg N, Nout RA, et al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer 2020; 30:2002.</a></li><li class="breakAll">Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER), 2021. Available at: https://clinicaltrials.gov/ct2/show/NCT04705649 (Accessed on June 14, 2021).</li><li><a class="nounderline abstract_t">Howitt BE, Shukla SA, Sholl LM, et al. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol 2015; 1:1319.</a></li><li><a class="nounderline abstract_t">Santin AD, Bellone S, Buza N, et al. Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab. Clin Cancer Res 2016; 22:5682.</a></li><li><a class="nounderline abstract_t">Talhouk A, Derocher H, Schmidt P, et al. Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. Clin Cancer Res 2019; 25:2537.</a></li><li><a class="nounderline abstract_t">McConechy MK, Talhouk A, Li-Chang HH, et al. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol Oncol 2015; 137:306.</a></li><li><a class="nounderline abstract_t">Rudd ML, Price JC, Fogoros S, et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 2011; 17:1331.</a></li><li class="breakAll">FDA approves first cancer treatment for any solid tumor with a specific genetic feature. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication (Accessed on May 04, 2020).</li><li><a class="nounderline abstract_t">Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372:2509.</a></li><li><a class="nounderline abstract_t">Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med 2023; 388:2145.</a></li><li><a class="nounderline abstract_t">Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med 2023; 388:2159.</a></li><li><a class="nounderline abstract_t">Vermij L, Jobsen JJ, León-Castillo A, et al. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry. Br J Cancer 2023; 128:1360.</a></li><li><a class="nounderline abstract_t">Jamieson A, Huvila J, Chiu D, et al. Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death. Mod Pathol 2023; 36:100085.</a></li><li><a class="nounderline abstract_t">Jamieson A, Thompson EF, Huvila J, et al. p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification. Int J Gynecol Cancer 2021; 31:907.</a></li><li><a class="nounderline abstract_t">Jamieson A, Huvila J, Leung S, et al. Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer. Gynecol Oncol 2023; 170:282.</a></li><li><a class="nounderline abstract_t">Vermij L, Horeweg N, Leon-Castillo A, et al. HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes. Cancers (Basel) 2020; 13.</a></li><li><a class="nounderline abstract_t">Fader AN, Roque DM, Siegel E, et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clin Cancer Res 2020; 26:3928.</a></li><li><a class="nounderline abstract_t">Ashley CW, Da Cruz Paula A, Kumar R, et al. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. Gynecol Oncol 2019; 152:11.</a></li><li><a class="nounderline abstract_t">de Jonge MM, de Kroon CD, Jenner DJ, et al. Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study. J Natl Cancer Inst 2021; 113:1203.</a></li><li><a class="nounderline abstract_t">Rubinstein MM, Dickinson S, Narayan P, et al. Bevacizumab in advanced endometrial cancer. Gynecol Oncol 2021; 161:720.</a></li><li><a class="nounderline abstract_t">Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. J Clin Oncol 2020; 38:2981.</a></li><li><a class="nounderline abstract_t">Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol 2016; 27:16.</a></li><li><a class="nounderline abstract_t">Klopp A, Smith BD, Alektiar K, et al. The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2014; 4:137.</a></li><li class="breakAll">PDQ Adult Treatment Editorial Board.. PDQ Cancer Information Summaries, National Cancer Institute (US), Bethesda (MD) 2002.</li><li><a class="nounderline abstract_t">SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, et al. Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol 2014; 134:385.</a></li><li><a class="nounderline abstract_t">SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, et al. Endometrial cancer: a review and current management strategies: part II. Gynecol Oncol 2014; 134:393.</a></li><li><a class="nounderline abstract_t">Lucas E, Chen H, Molberg K, et al. Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions? Int J Gynecol Pathol 2019; 38:533.</a></li><li><a class="nounderline abstract_t">Russo M, Broach J, Sheldon K, et al. Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma. Hum Pathol 2017; 67:69.</a></li><li><a class="nounderline abstract_t">Han G, Lim D, Leitao MM Jr, et al. Histological features associated with occult lymph node metastasis in FIGO clinical stage I, grade I endometrioid carcinoma. Histopathology 2014; 64:389.</a></li><li><a class="nounderline abstract_t">Hertel JD, Huettner PC, Pfeifer JD. Lymphovascular space invasion in microcystic elongated and fragmented (MELF)-pattern well-differentiated endometrioid adenocarcinoma is associated with a higher rate of lymph node metastasis. Int J Gynecol Pathol 2014; 33:127.</a></li><li><a class="nounderline abstract_t">Alkushi A, Lim P, Coldman A, et al. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol 2004; 23:129.</a></li><li><a class="nounderline abstract_t">Alvarez T, Miller E, Duska L, Oliva E. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? Am J Surg Pathol 2012; 36:753.</a></li><li><a class="nounderline abstract_t">Voss MA, Ganesan R, Ludeman L, et al. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation. Gynecol Oncol 2012; 124:15.</a></li><li><a class="nounderline abstract_t">Singh N, Hirschowitz L, Zaino R, et al. Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade). Int J Gynecol Pathol 2019; 38 Suppl 1:S93.</a></li><li><a class="nounderline abstract_t">Yano M, Ito K, Yabuno A, et al. Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma. Mod Pathol 2019; 32:1023.</a></li><li><a class="nounderline abstract_t">Huang CY, Tang YH, Chiang YC, et al. Impact of management on the prognosis of pure uterine papillary serous cancer - a Taiwanese Gynecologic Oncology Group (TGOG) study. Gynecol Oncol 2014; 133:221.</a></li><li><a class="nounderline abstract_t">Fadare O, Zheng W, Crispens MA, et al. Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases. Am J Cancer Res 2013; 3:70.</a></li><li><a class="nounderline abstract_t">DeLair DF, Burke KA, Selenica P, et al. The genetic landscape of endometrial clear cell carcinomas. J Pathol 2017; 243:230.</a></li><li><a class="nounderline abstract_t">Hoang LN, McConechy MK, Meng B, et al. Targeted mutation analysis of endometrial clear cell carcinoma. Histopathology 2015; 66:664.</a></li><li><a class="nounderline abstract_t">Schultheis AM, Ng CK, De Filippo MR, et al. Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. J Natl Cancer Inst 2016; 108:djv427.</a></li><li><a class="nounderline abstract_t">Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 2006; 106:87.</a></li><li><a class="nounderline abstract_t">Murali R, Davidson B, Fadare O, et al. High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations. Int J Gynecol Pathol 2019; 38 Suppl 1:S40.</a></li><li><a class="nounderline abstract_t">Travaglino A, Raffone A, Mascolo M, et al. TCGA Molecular Subgroups in Endometrial Undifferentiated/Dedifferentiated Carcinoma. Pathol Oncol Res 2020; 26:1411.</a></li><li><a class="nounderline abstract_t">Sreenan JJ, Hart WR. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 1995; 19:666.</a></li><li><a class="nounderline abstract_t">Gotoh O, Sugiyama Y, Takazawa Y, et al. Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma. Nat Commun 2019; 10:4965.</a></li><li><a class="nounderline abstract_t">Cherniack AD, Shen H, Walter V, et al. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell 2017; 31:411.</a></li><li class="breakAll">Matias-Guiu X, Anderson L, Buza N, Ellenson LH, Fadare O, Ganesan R, Ip PPC, Palacios J, Parra-Herran C, Raspollini MR, Soslow RA, Werner HMJ, Lax SF, McCluggage WG (2021). Endometrial Cancer Histopathology Reporting Guide. 4th edition. International Collaboration on Cancer Reporting; Sydney, Australia.</li><li class="breakAll">BAGP POLE NGS testing guidance. British Gynaecological Cancer Society. Available at: https://www.bgcs.org.uk/wp-content/uploads/2022/04/BAGP-POLE-testing-in-Endometrial-cancer-v1.1-2022-04-08.pdf (Accessed on August 10, 2023).</li><li><a class="nounderline abstract_t">Erickson BK, Najjar O, Damast S, et al. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. Gynecol Oncol 2020; 159:17.</a></li></ol></div><div id="topicVersionRevision">Topic 3192 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6822361" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Two pathogenetic types of endometrial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6822361" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Two pathogenetic types of endometrial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37337978" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : FIGO staging of endometrial cancer: 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33397713" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33397713" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35690222" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23636398" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Integrated genomic characterization of endometrial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31472940" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : TCGA molecular groups of endometrial cancer: Pooled data about prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32296930" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32253551" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : TCGA molecular subgroups and FIGO grade in endometrial endometrioid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31433862" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clear cell endometrial carcinoma and the TCGA classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27308732" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Endometrial cancer: Not your grandmother's cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30922603" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32331700" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24556061" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29505428" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31829447" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31829442" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Interpretation of somatic POLE mutations in endometrial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14984936" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30995174" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24999075" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device±metformin±weight loss in endometrial cancer (feMME) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12529349" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31345626" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32749941" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31103324" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37487144" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29449189" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30413523" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29584549" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33541735" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31677820" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33937919" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Impact of Molecular Classification on Treatment Paradigms in Uterine Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31248668" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29432521" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27421752" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27006490" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28079598" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26172027" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A clinically applicable molecular-based classification for endometrial cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28061006" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35397864" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11988770" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The 3' 5' exonucleases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26822575" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A panoply of errors: polymerase proofreading domain mutations in cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24861832" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : DNA polymeraseεand its roles in genome stability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23528559" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : DNA polymeraseεandδexonuclease domain mutations in endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25505230" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prognostic significance of POLE proofreading mutations in endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26763250" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24844595" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31757464" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33793971" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33793971" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33046573" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33046573" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26181000" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27486176" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Regression of Chemotherapy-Resistant Polymeraseε(POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30523022" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25636458" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21266528" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21266528" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26028255" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36972026" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36972022" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36690721" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36788084" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33589443" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36753816" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33375706" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32601075" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30415991" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33710348" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33894982" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Bevacizumab in advanced endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32167863" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26634381" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24766678" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24766678" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24905773" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Endometrial cancer: a review and current management strategies: part I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24929052" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Endometrial cancer: a review and current management strategies: part II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383610" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28712776" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24215212" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Histological features associated with occult lymph node metastasis in FIGO clinical stage I, grade I endometrioid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24487466" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Lymphovascular space invasion in microcystic elongated and fragmented (MELF)-pattern well-differentiated endometrioid adenocarcinoma is associated with a higher rate of lymph node metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15084841" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22498825" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21864888" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30550486" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30742011" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24556064" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Impact of management on the prognosis of pure uterine papillary serous cancer - a Taiwanese Gynecologic Oncology Group (TGOG) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23359866" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28718916" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The genetic landscape of endometrial clear cell carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25308272" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Targeted mutation analysis of endometrial clear cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26832770" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16323174" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30550483" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31811476" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : TCGA Molecular Subgroups in Endometrial Undifferentiated/Dedifferentiated Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7755153" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31672974" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28292439" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Integrated Molecular Characterization of Uterine Carcinosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28292439" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Integrated Molecular Characterization of Uterine Carcinosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28292439" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Integrated Molecular Characterization of Uterine Carcinosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32709539" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
